(Q28255366)

Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase

21 January 2018

1 reference

The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases

21 January 2018

1 reference

Rapamycin resistance tied to defective regulation of p27Kip1.

21 January 2018

1 reference

The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.

21 January 2018

1 reference

Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines

21 January 2018

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis

21 January 2018

1 reference

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways

31 March 2020

1 reference

31 March 2020

Protein kinase C delta

1 reference

Distinctive activation mechanisms and functions for protein kinase Cdelta

31 March 2020

1 reference

The MAPK signalling pathways and colorectal cancer

31 March 2020

1 reference

The Akt-mTOR tango and its relevance to cancer

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

Dysregulation of the TSC-mTOR pathway in human disease

31 March 2020

1 reference

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

31 March 2020

1 reference

AMPK, the metabolic syndrome and cancer

31 March 2020

1 reference

The LKB1 tumor suppressor negatively regulates mTOR signaling

31 March 2020

1 reference

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models

31 March 2020

1 reference

TOR signalling and control of cell growth

31 March 2020

1 reference

TOR, a central controller of cell growth

31 March 2020

1 reference

An expanding role for mTOR in cancer

31 March 2020

1 reference

The expanding TOR signaling network

31 March 2020

1 reference

Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway

31 March 2020

1 reference

Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.

31 March 2020

1 reference

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

31 March 2020

1 reference

Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase

31 March 2020

1 reference

Insulin-like growth factors and breast cancer

31 March 2020

1 reference

Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

31 March 2020

1 reference

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

31 March 2020

1 reference

Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk

31 March 2020

1 reference

Insulin-like growth factor physiology and cancer risk

31 March 2020

1 reference

Role of the insulin-like growth factor family in cancer development and progression

31 March 2020

1 reference

The role of the insulin-like growth factor I receptor in transformation and apoptosis.

31 March 2020

1 reference

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

31 March 2020

1 reference

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

31 March 2020

1 reference

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

31 March 2020

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

31 March 2020

1 reference

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

31 March 2020

1 reference

Regulation of eIF-4E BP1 phosphorylation by mTOR.

31 March 2020

1 reference

PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase

31 March 2020

1 reference

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

31 March 2020

1 reference

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

31 March 2020

1 reference

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

31 March 2020

1 reference

Initiation of protein synthesis in eukaryotic cells

31 March 2020

1 reference

The mRNA 5' cap-binding protein eIF4E and control of cell growth

31 March 2020

1 reference

IRS-1: auditing the effectiveness of mTOR inhibitors

31 March 2020

1 reference

Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels

31 March 2020

1 reference

Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E.

31 March 2020

1 reference

cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells

31 March 2020

1 reference

Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degradation, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinase-independent pathway

31 March 2020

1 reference

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

31 March 2020

1 reference

4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase

31 March 2020

1 reference

The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus

31 March 2020

1 reference

Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes

31 March 2020

1 reference

The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites

31 March 2020

1 reference

Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases

31 March 2020

1 reference

Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin

31 March 2020

1 reference

Control of p70 s6 kinase by kinase activity of FRAP in vivo

31 March 2020

1 reference

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

31 March 2020

1 reference

cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells

31 March 2020

1 reference

Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin

31 March 2020

1 reference

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

31 March 2020

1 reference

Modulation of transcription of rRNA genes by rapamycin

31 March 2020

1 reference

Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control?

31 March 2020

1 reference

Phosphatidylinositol-3-OH kinase as a direct target of Ras

31 March 2020

1 reference

The coordinate regulation of the p53 and mTOR pathways in cells

31 March 2020

1 reference

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

31 March 2020

1 reference

Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells

31 March 2020

1 reference

Silencing of thePTENtumor-suppressor gene in anaplastic thyroid cancer

31 March 2020

1 reference

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling

31 March 2020

1 reference

Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells

31 March 2020

1 reference

Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival

31 March 2020

1 reference

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

31 March 2020

1 reference

EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer

31 March 2020

1 reference

Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer

31 March 2020

1 reference

Epigenetic and genetic alternation of PTEN in cervical neoplasm.

31 March 2020

1 reference

Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast

31 March 2020

1 reference

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

31 March 2020

1 reference

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

31 March 2020

1 reference

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

31 March 2020

1 reference

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

31 March 2020

1 reference

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells

31 March 2020

1 reference

Lack of somatic mutation in the PTEN gene in squamous cell carcinomas of human skin.

31 March 2020

1 reference

Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma

31 March 2020

1 reference

The prevalence of PIK3CA mutations in gastric and colon cancer.

31 March 2020

1 reference

Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells

31 March 2020

1 reference

Mutations of PIK3CA in gastric adenocarcinoma

31 March 2020

1 reference

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

31 March 2020

1 reference

Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines

31 March 2020

1 reference

Therapeutic monitoring of rapamycin: a new immunosuppressive drug.

31 March 2020

1 reference

Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival

31 March 2020

1 reference

Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update

31 March 2020

1 reference

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

31 March 2020

1 reference

Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle

31 March 2020

1 reference

Use of rapamycin-impregnated stents in coronary arteries

31 March 2020

1 reference

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

31 March 2020

1 reference

Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain

31 March 2020

1 reference

Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope

31 March 2020

1 reference

Inhibition of the Phosphatidylinositol 3-Kinase/p70S6-Kinase Pathway Induces B16 Melanoma Cell Differentiation

31 March 2020

1 reference

Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase.

31 March 2020

1 reference

Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production

31 March 2020

1 reference

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

31 March 2020

1 reference

Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors

31 March 2020

1 reference

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

31 March 2020

1 reference

Inhibition of macroautophagy triggers apoptosis

31 March 2020

1 reference

Lysosomes and autophagy in cell death control

31 March 2020

1 reference

The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis

31 March 2020

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

31 March 2020

1 reference

Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription

31 March 2020

1 reference

Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells

31 March 2020

1 reference

Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.

31 March 2020

1 reference

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

31 March 2020

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

31 March 2020

1 reference

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

31 March 2020

1 reference

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

31 March 2020

1 reference

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

31 March 2020

1 reference

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

31 March 2020

1 reference

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

31 March 2020

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

31 March 2020

1 reference

The Akt/PKB pathway: molecular target for cancer drug discovery

31 March 2020

1 reference

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

31 March 2020

1 reference

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

31 March 2020

1 reference

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

31 March 2020

1 reference

Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity

31 March 2020

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

31 March 2020

1 reference